Whitehawk Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.1M | $26.0M | $24.4M | $15.2M | $14.0M | $14.0M | $0 | $20.2M |
| Cost of Revenue | $760.0K | $3.0M | $2.8M | $1.3M | $0 | — | — | — |
| Gross Profit | $6.4M | $23.0M | $21.5M | $13.9M | $14.0M | — | — | — |
| Gross Margin | 89.4% | 88.4% | 88.5% | 91.2% | 100.0% | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $91.0M | $51.0M | $48.9M | $32.7M | $19.7M | $15.0M | $12.8M | $17.9M |
| SG&A Expense | $29.8M | $36.7M | $44.5M | $40.2M | $18.5M | $2.1M | $9.8M | $13.5M |
| Operating Income | $-114.4M | $-67.5M | $-71.9M | $-62.7M | $-111.2M | $-2.5M | $-24.4M | $-11.2M |
| Operating Margin | -1,601.1% | -259.6% | -295.4% | -411.9% | -794.4% | -18.2% | — | -55.5% |
| Interest Expense | — | — | $231.0K | $230.0K | $665.0K | $815.0K | — | — |
| Pretax Income | $-20.6M | $-63.7M | $-65.8M | $-60.5M | $-110.1M | $-3.5M | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $2.0K | $2.0K | — | — |
| Net Income | $-20.6M | $-63.7M | $-65.8M | $-60.5M | $-110.1M | $-3.5M | $-23.3M | $-10.4M |
| Net Margin | -288.3% | -245.1% | -270.0% | -397.7% | -786.4% | -24.8% | — | -51.6% |
| EPS (Basic) | $-0.33 | $-1.18 | $-1.22 | $-1.35 | $-2.07 | $-0.29 | $-0.10 | $-0.05 |
| EPS (Diluted) | $-0.33 | $-1.18 | $-1.22 | $-1.35 | $-2.07 | $-0.29 | $-0.10 | $-0.05 |
| Shares Outstanding (Basic) | 61.9M | 54.1M | 53.8M | 45.0M | 53.5M | 15.3M | 243.5M | 243.5M |
| Shares Outstanding (Diluted) | 61.9M | 54.1M | 53.8M | 45.0M | 53.5M | 15.3M | 243.5M | 243.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |